Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-03-27-Speech-4-017"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20030327.1.4-017"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, I hope that we will soon adopt the Caudron report with a substantial majority at first reading. The rapporteur has already cited the figures. Millions of people in developing countries are dying of HIV/AIDS, malaria and tuberculosis every year. They are poverty diseases, as has also already been said.
These diseases account for a large proportion of serious illness, but up to now have had only a small research budget. The help that has been offered up to now has been predominantly therapeutic, and also in the form of information regarding causes and prevention options. What is special about the project that we are now discussing is that it has the potential to give an impetus to the development of new technologies and new safe, effective drugs for combating these diseases.
The research taking place in this field in the European Union is very fragmented, and very few networks have been established, which has resulted in organisational and economic obstacles to large-scale research and trials. It is right, therefore, that this proposal makes use of Article 169 of the Treaty, which indeed enables the participation of the European Union in joint research and development programmes.
As has already been said, this is a first, and in my view the experiment is definitely worth the while. I hope that it will constitute a good start to more intensive cooperation in many fields within the EU.
A very important criterion for our group was that the countries where these diseases are widespread be involved intensively in the setting up, and participate fully in the implementation, of the programme from the outset, and that a large number of the trials take place on site there. Another point important to our group was that the programme should make a contribution towards capacity-building in the developing countries and ensuring the availability of good, affordable drugs in those countries. In addition, we, too, value the involvement of the private sector.
By way of conclusion, I am of course proud that the Netherlands has managed to qualify to be allocated a seat of the executive office of the EDCTP. The Netherlands will devote maximum efforts to making this project a success."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples